FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W53279618> ?p ?o ?g. }

• W53279618 abstract "Facilitation of margin-negative resection is the goal of neoadjuvant therapy regimens used in the treatment of borderline-resectable pancreatic cancer patients. Multiple treatment approaches have shown efficacy in this setting, including neoadjuvant GTX (gemcitabine [Gemzar], docetaxel [Taxotere], and capecitabine [Xeloda]) and radiotherapy (RT). Three-dimensional tumor response may be a more accurate method of assessment compared to traditional 1- and 2-dimensional techniques. We compared these 3 methods in a series of patients who underwent neoadjuvant GTX-RT and surgical resection.This retrospective review included borderline-resectable pancreatic cancer patients treated with neoadjuvant GTX followed by 5-FU chemoradiotherapy with the intent of downstaging to resectability. Tumor was contoured on computed tomography (CT) scans obtained at the following time points: (A) initial staging, (B) CT simulation, and (C) restaging. These contours were used to determine tumor response according to WHO, RECIST, and volumetric criteria.Fourteen patients all experienced a measurable decrease in tumor volume following neoadjuvant therapy and were deemed suitable for at least surgical exploration. Radiotherapy was delivered to a median 50 Gy (range, 45-52 Gy) in 1.8-2.0 Gy fractions via 3-D conformal (21%) or IMRT (79%). The median percent volume changes before and after CT simulation were -3.4% and -52.6%, respectively. The overall median percent change was -54.5%. The corresponding absolute volume changes were -0.42 cm(3) (range, 9.12 to -12.47), -5.31 cm(3) (range, 2.06 to -15.93), and -6.72 cm(3) (range, 0.53 to -15.47), respectively. Response according to WHO, RECIST, and volumetric methods was identical with the exception of 1 patient.This is the first study to quantify volumetric tumor change objectively as a result of neoadjuvant chemoradiotherapy for the treatment of borderline resectable pancreatic cancer. Our data suggest that tumor response to neoadjuvant therapy is essentially equivalent between 1-, 2-, and 3-dimensional assessment methods." @default.
• W53279618 created "2016-06-24" @default.
• W53279618 creator A5005718112 @default.
• W53279618 creator A5006838528 @default.
• W53279618 creator A5012399386 @default.
• W53279618 creator A5016061217 @default.
• W53279618 creator A5029626497 @default.
• W53279618 creator A5034828239 @default.
• W53279618 creator A5035589941 @default.
• W53279618 creator A5047712976 @default.
• W53279618 creator A5062142011 @default.
• W53279618 creator A5063242255 @default.
• W53279618 date "2011-07-01" @default.
• W53279618 modified "2023-10-02" @default.
• W53279618 title "Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer." @default.
• W53279618 cites W1534429452 @default.
• W53279618 cites W171510207 @default.
• W53279618 cites W1892409143 @default.
• W53279618 cites W1931508686 @default.
• W53279618 cites W1940632416 @default.
• W53279618 cites W1970580715 @default.
• W53279618 cites W1974219858 @default.
• W53279618 cites W1975845802 @default.
• W53279618 cites W1976253905 @default.
• W53279618 cites W1979659182 @default.
• W53279618 cites W1987814657 @default.
• W53279618 cites W1992642679 @default.
• W53279618 cites W1993369777 @default.
• W53279618 cites W1999487092 @default.
• W53279618 cites W2004009260 @default.
• W53279618 cites W2005492562 @default.
• W53279618 cites W2007506726 @default.
• W53279618 cites W2012882585 @default.
• W53279618 cites W2018678771 @default.
• W53279618 cites W2023890601 @default.
• W53279618 cites W2024816862 @default.
• W53279618 cites W2027140244 @default.
• W53279618 cites W2027227966 @default.
• W53279618 cites W2029845350 @default.
• W53279618 cites W2036796187 @default.
• W53279618 cites W2043046437 @default.
• W53279618 cites W2044211072 @default.
• W53279618 cites W2050023459 @default.
• W53279618 cites W2050643752 @default.
• W53279618 cites W2076090272 @default.
• W53279618 cites W2077003423 @default.
• W53279618 cites W2079934168 @default.
• W53279618 cites W2080202323 @default.
• W53279618 cites W2081623967 @default.
• W53279618 cites W2088236952 @default.
• W53279618 cites W2090721857 @default.
• W53279618 cites W2091405318 @default.
• W53279618 cites W2096900586 @default.
• W53279618 cites W2100520788 @default.
• W53279618 cites W2103436098 @default.
• W53279618 cites W2107907914 @default.
• W53279618 cites W2108089177 @default.
• W53279618 cites W2139248078 @default.
• W53279618 cites W2150437164 @default.
• W53279618 cites W2160609033 @default.
• W53279618 cites W2161060804 @default.
• W53279618 cites W2167628315 @default.
• W53279618 cites W2183779534 @default.
• W53279618 cites W2256983341 @default.
• W53279618 cites W2411064936 @default.
• W53279618 cites W3134530972 @default.
• W53279618 cites W88439298 @default.
• W53279618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3283109" @default.
• W53279618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22368736" @default.
• W53279618 hasPublicationYear "2011" @default.
• W53279618 type Work @default.
• W53279618 sameAs 53279618 @default.
• W53279618 citedByCount "6" @default.
• W53279618 countsByYear W532796182013 @default.
• W53279618 countsByYear W532796182015 @default.
• W53279618 countsByYear W532796182016 @default.
• W53279618 countsByYear W532796182018 @default.
• W53279618 countsByYear W532796182022 @default.
• W53279618 crossrefType "journal-article" @default.
• W53279618 hasAuthorship W53279618A5005718112 @default.
• W53279618 hasAuthorship W53279618A5006838528 @default.
• W53279618 hasAuthorship W53279618A5012399386 @default.
• W53279618 hasAuthorship W53279618A5016061217 @default.
• W53279618 hasAuthorship W53279618A5029626497 @default.
• W53279618 hasAuthorship W53279618A5034828239 @default.
• W53279618 hasAuthorship W53279618A5035589941 @default.
• W53279618 hasAuthorship W53279618A5047712976 @default.
• W53279618 hasAuthorship W53279618A5062142011 @default.
• W53279618 hasAuthorship W53279618A5063242255 @default.
• W53279618 hasConcept C121608353 @default.
• W53279618 hasConcept C126322002 @default.
• W53279618 hasConcept C126838900 @default.
• W53279618 hasConcept C143998085 @default.
• W53279618 hasConcept C2776694085 @default.
• W53279618 hasConcept C2777909004 @default.
• W53279618 hasConcept C2778292576 @default.
• W53279618 hasConcept C2778424827 @default.
• W53279618 hasConcept C2779984678 @default.
• W53279618 hasConcept C2780210213 @default.
• W53279618 hasConcept C2780258809 @default.

• next